Mirati Therapeutics: Innovating Stellar Molecules For Cancer Treatment | Latest News RSS feed

Mirati Therapeutics: Innovating Stellar Molecules For Cancer Treatment - Latest News


Mirati Therapeutics: Innovating Stellar Molecules For Cancer Treatment

Mirati is a gift that keeps on giving, as the company logged astronomical profits for shareholders. Powered by a broad and high-quality pipeline, there are more “shots on goal” of finding a ... read more

BeiGene and Mirati Therapeutics Announce Exclusive License Agreement for Sitravatinib in the Asia Pacific Region

10.71% a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, and Mirati ... read more

Histone Deacetylases (HDAC) Inhibitors Market, Players, trends and forecast 2016 - 2026

Approval of the first HDAC inhibitor, Zolinza™ (vorinostat), in 2006 for treatment of CTCL gave the market an initial impetus. The momentum was carried on by the other molecules that ... Karus ... read more

Looking for another news?


Galera's big-money drug has roots in Monsanto lab

The drug responsible for this week’s $150 million investment in Galera Therapeutics, the largest single capital ... cells from the harmful effects of radiation, which is used in cancer treatment. ... read more


MD Anderson and Accelerator Life Science Partners launch Magnolia Neurosciences

The University of Texas MD Anderson Cancer ... Therapeutics Discovery division is a unique group of more than 100 clinicians, researchers and drug discovery scientists at MD Anderson working to ... read more

Curis Expands Senior Management Expertise with Appointment of Robert Martell, M.D., Ph.D., as Head of Research and Development

May 24, 2018 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer ... as ... read more

Biotech Stock Performance Review -- Jaguar Health, Kitov Pharma, MabVax Therapeutics, and Mirati Therapeutics

On October 12 [th] , 2017, Mirati Therapeutics announced that it has been included in the SU2C Catalyst [[] [TM] []] program, a cutting-edge research initiative, led by Stand Up To Cancer (SU2C) ... read more

Dr. Emil Frei III Establishes a New Cancer Services Platform

Dr. Emil Frei III Establishes a New Cancer Services Platform Email Print ... Molecular science by identifying target molecules on tumor cells is producing new agents-agents for ... By participating in ... read more

People on the Move: Specialty Companies

Chris LeMasters was appointed to the newly created position of executive VP and chief business officer of Mirati Therapeutics Inc. Before joining ... information to physicians to improve cancer ... read more

A breakthrough in lung cancer – the biggest prize in immunotherapy

... cancer treatment. The drugs and drug combinations which emerge as the best in extending cancer survival and improving quality of life – especially the current death-sentence of NSCLC – will see ... read more

Blue Chip Biotech Highlights Jefferies 4 Top Growth Stocks to Buy Now

Acadia has posted stellar earnings ... Insys Therapeutics Inc. (NASDAQ: INSY) is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of ... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us